Clinical Trial Update: A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia [Phase 3]

View source ↗

Summary

A Phase 3 pediatric CKD trial comparing Velphoro (PA21) and Phoslyra (calcium acetate) for hyperphosphatemia was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• Phoslyra (calcium acetate)
• VELPHORO (sucroferric oxyhydroxide)

Snippet

Sponsor: Vifor Fresenius Medical Care Renal Pharma | Conditions: Hyperphosphatemia | Phase 3 | Status: TERMINATED | Results posted: 2019-08-28